Contrad Swiss in new partnership with Dr JO Serrentino

Contrad Swiss in new partnership with Dr JO Serrentino

June 26, 2019 Off By BusinessWire

LUGANO, Switzerland–(BUSINESS WIRE)–#Antiaging–Contrad Swiss, a pharmaceutical company focused on breakthrough, innovative products that reframe the world of medicine, announces a new partnership with Dr JO Serrentino.


SIGMOLECS Technology was conceived and engineered by Dr Serrentino exclusively for Contrad Swiss.

SIGMOLECS uses the highest bioavailable signaling molecules to summon and target biological pathways for precise programming at the cellular level. The result is like a program code of the cells, deploying them to organize into specific patterns. SIGMOLECS talks to the cells in their language.

ACTV8SKN – Actuator – contains the exclusive SIGMOLECS Technology.

ACTV8SKN is an odorless fluid gel of peptide-bonded amino acids, specifically engineered for a complete signaling spectrum that awakens cell cycles of the skin. It can be used in clinic to enhance procedures or dispensed to patients as a follow up take-home product. Easy to use, a few drops of ACTV8SKN to cleansed face. The fluid gel will absorb as soon as it is spread.